These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27013130)

  • 1. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
    Xiong H; Zhou Y; Zhou Q; He D; Deng X; Sun Q; Zhang J
    Nanomedicine; 2016 Aug; 12(6):1557-66. PubMed ID: 27013130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanosomal Microassemblies for Highly Efficient and Safe Delivery of Therapeutic Enzymes.
    Xiong H; Zhou Y; Zhou Q; He D; Wan S; Tan Q; Zhang M; Deng X; Zhang J
    ACS Appl Mater Interfaces; 2015 Sep; 7(36):20255-63. PubMed ID: 26325262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
    Deng X; He D; Xiong HR; Zhou YL; Zhang JQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):688-91. PubMed ID: 26619536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
    Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
    Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
    PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uricase and Horseradish Peroxidase Hybrid CaHPO₄ Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia.
    Hao Y; Li H; Cao Y; Chen Y; Lei M; Zhang T; Xiao Y; Chu B; Qian Z
    J Biomed Nanotechnol; 2019 May; 15(5):951-965. PubMed ID: 30890227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice.
    Tran L; Das S; Zhao L; Finn MG; Gaucher EA
    Biomacromolecules; 2023 May; 24(5):2003-2008. PubMed ID: 37126604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes.
    Zhou Y; Zhang M; He D; Hu X; Xiong H; Wu J; Zhu B; Zhang J
    Sci Rep; 2016 Jan; 7():20136. PubMed ID: 26823332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocapsules of therapeutic proteins with enhanced stability and long blood circulation for hyperuricemia management.
    Zhang X; Xu D; Jin X; Liu G; Liang S; Wang H; Chen W; Zhu X; Lu Y
    J Control Release; 2017 Jun; 255():54-61. PubMed ID: 28288895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of lipid vesicles containing uricase.
    Tan QY; Wang N; Yang H; Chen L; Xiong HR; Zhang LK; Liu J; Zhao CJ; Zhang JQ
    Drug Deliv; 2010 Jan; 17(1):28-37. PubMed ID: 22747073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal delivery of a therapeutic enzyme.
    Zhang C; Pu J; Yang X; Feng T; Liu F; Wang D; Hu X; Gao A; Liu H; Zhan CG; Liao F
    Sci Rep; 2016 Aug; 6():30888. PubMed ID: 27477538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
    Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
    Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.
    Tan QY; Zhang JQ; Wang N; Yang H; Li X; Xiong HR; Wu JY; Zhao CJ; Wang H; Yin HF
    Int J Nanomedicine; 2012; 7():3929-38. PubMed ID: 22915844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein.
    Tong M; Wang S; Luan J; Xie Q; Wang L; Shen X; Xiong S
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):131989. PubMed ID: 38697425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Cascade Nanoreactor Integrating Two-Dimensional Pd-Ru Nanozyme, Uricase and Red Blood Cell Membrane for Highly Efficient Hyperuricemia Treatment.
    Ming J; Zhu T; Li J; Ye Z; Shi C; Guo Z; Wang J; Chen X; Zheng N
    Small; 2021 Nov; 17(46):e2103645. PubMed ID: 34668309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of therapeutic protein and catalase-mimic nanoparticle using a biocompatible nanocarrier for enhanced therapeutic effect.
    Kim S; Kim M; Jung S; Kwon K; Park J; Kim S; Kwon I; Tae G
    J Control Release; 2019 Sep; 309():181-189. PubMed ID: 31356840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.